Show simple item record

dc.contributor.authorCheleschi, S
dc.contributor.authorPascarelli, NA
dc.contributor.authorValacchi, G
dc.contributor.authorDi Capua, A
dc.contributor.authorBiava, M
dc.contributor.authorBelmonte, G
dc.contributor.authorGiordani, A
dc.contributor.authorSticozzi, C
dc.contributor.authorAnzini, M
dc.contributor.authorFioravanti, A
dc.date.accessioned2017-08-14T03:26:28Z
dc.date.available2017-08-14T03:26:28Z
dc.date.issued2015
dc.identifier.issn1567-5769
dc.identifier.doi10.1016/j.intimp.2015.07.003
dc.identifier.urihttp://hdl.handle.net/10072/343963
dc.description.abstractVA694, a promising cyclooxigenase-2 (COX-2)-inhibiting hybrid drug endowed with nitric oxide (NO) releasing properties (NO-COXIB), showed COX-2-selective inhibitory effects, associated with interesting anti-inflammatory and anti-nociceptive activities. Therefore, we studied the effects of VA694 on cartilage metabolism, in comparison with Naproxcinod, a COX inhibitor and NO donor (CINOD), and Naproxen, a traditional non-steroidal–anti-inflammatory drug (NSAID) on human osteoarthritic chondrocyte cultures. IL-1β-stimulated chondrocytes showed a significant decrease in cell viability (P < 0.001). VA694, Naproxcinod and Naproxen alone didn't significantly affect cell viability, while it restored cell viability in cultures stimulated by IL-1β. The presence of IL-1β determined a significant increase (P < 0.001) in PGE2 levels measured by an ELISA assay, and in COX-2 and MMP-3, -9, and -13 gene expression analyzed by RT-PCR. VA694, Naproxcinod and Naproxen, at both concentrations analyzed, significantly counteracted the negative effects induced by IL-1β. VA694, Naproxcinod and Naproxen pre-treatment were able to inhibit IL-1β-induced NF-κB activation, when measured as its nuclear translocation (p50 and p65 subunits). Naproxcinod and Naproxen pre-treatment didn't affect cytoplasmic NF-κB levels; VA694 decreased the cytoplasmic levels of both subunits. Our data suggest that VA694, Naproxcinod and Naproxen, exert anti-inflammatory and chondroprotective effects on OA chondrocytes.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherElsevier
dc.relation.ispartofpagefrom794
dc.relation.ispartofpageto801
dc.relation.ispartofissue1
dc.relation.ispartofjournalInternational Immunopharmacology
dc.relation.ispartofvolume28
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences not elsewhere classified
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchcode111599
dc.subject.fieldofresearchcode1115
dc.titleChondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorDi Capua, Angela


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record